top of page
Browse by category
Search
United Biotechnology and Novo Nordisk agree license for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
The United Laboratories International Holdings Limited’s (TUL) wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd....
Novo Nordisk completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
Novo Nordisk has announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor...
Variant Bio and Novo Nordisk sign multi-year research partnership to discover novel targets for metabolic disease
Variant Bio has announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the treatment of metabolic...
REDEFINE 1 trial: CagriSema demonstrates superior weight loss in adults with obesity or overweight
Headline results from Novo Nordisk’s REDEFINE 1 has shown that the trial achieved its primary endpoint by demonstrating a statistically...
Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide
Novo Nordisk is planning a study that will see CagriSema, a new investigational medicine developed by Novo that combines Cagrilintide and...
GE HealthCare and Novo Nordisk to collaborate on peripheral focused ultrasound for T2DM and obesity
GE HealthCare and Novo Nordisk are collaborating to further advance the clinical and product development of peripheral focused ultrasound...
Novo Nordisk to end semaglutide kidney study early due to strong efficacy signals
Novo Nordisk is ending its Phase III FLOW trial ahead of schedule after an interim analysis of the kidney outcomes study of semaglutide...
Novo Nordisk to protect US patients from unlawful sales of non-FDA approved ‘semaglutide medicines’
Novo Nordisk is taking multiple actions to protect US patients from the unlawful marketing and sales of non-FDA approved counterfeit and...
Novo Nordisk to enter RNA market with Dicerna purchase
Denmark's Novo Nordisk, the world's leading insulin maker, has revealed it will buy US-based Dicerna Pharmaceuticals, a developer of RNA...
FDA approves Novo Nordisk’s Wegovy (semaglutide 2.4 mg) for weight management
The FDA has approved Novo Nordisk’s Wegovy (the brand name for once-weekly semaglutide 2.4mg injection in the US) for chronic weight...
Browse by tag
bottom of page